Navigation Links
DuPont Biotech Stewardship Program Gains External Certification
Date:2/17/2009

Third-Party Audit Confirms Responsible Use.

Wilmington, DE (Vocus) February 17, 2009 -- DuPont today announced that third-party audits have verified its plant biotechnology research and development processes are in compliance with the Excellence Through StewardshipSM (ETS) initiative for its North American operations. The ETS third-party audit confirms that the company uses the tools of biotechnology ethically and responsibly.

“As a long-term leader in safety, quality and stewardship, DuPont championed development of ETS within the industry,” said Paul E. Schickler, Pioneer president and DuPont vice president and general manager. “We are pleased that the third-party audit confirmed our processes meet the rigorous requirements of the stewardship initiative.

“Plant biotechnology holds tremendous promise to help us sustainably produce enough food, feed, fuel and biomaterials for a growing world, Schickler added. “ETS confirms we are using the technology responsibly and ensures we will continue our commitment well into the future.”

Excellence Through Stewardship is the first biotechnology industry coordinated initiative to provide stewardship and quality management programs for the full product life cycle of biotech-derived plant products. DuPont and other companies that attain certification are committing to promoting responsible use of biotechnology.

“We applaud DuPont -- and the other ETS founding membe
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
3. DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration
4. DuPont Named Among Top Biotechnology Employers by Science Magazine
5. Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize
6. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
7. DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest
8. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
9. DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum
10. DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DuPont Biotech Stewardship Program Gains External Certification
DuPont Biotech Stewardship Program Gains External Certification
(Date:12/2/2009)...SINGAPORE, Dec. 2 S*BIO Pte Ltd to... JAK2 inhibitor, SB1518, at The American Society o... New Orleans. ,, Data will be presented on the ...trial of SB1518 detailing its safety, tolerability...le in dose levels ranging from 100 to 600 mg. Thes...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world i...n turmoil and uncertainty is part of many,business...dustry has been,relatively immune to the economic ... , During the midst of the difficult time...; Johnson inaugurated an R&D center in Shangha...
(Date:12/1/2009)... VILLAGE, Nev., Dec. 1 P...nounced revenue guidance for the fourth quarter en..., as compared with $69 million for the fourth quar...ts was the first of two installment payments of $1... quarter 2008 results was a one-time $1.8 million ...
(Date:12/1/2009)...TH, Mass., Dec. 1 Harvest Technolo... results from the company sponsored 60-patient cli...enter in Chennai, India using the company,s BMAC S...ritical Limb Ischemia (CLI). Sri Ramachandra Medic...iated institution based in Chennai, India and one ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...g Term Development Agreement to Produce Reference ...e Cancer Research, NEWARK, Del., April 3, 2008 S...ader in providing advanced antibody,products and s...at it has,been selected by Science Applications In...evelop monoclonal antibodies for the Proteomics Re...
... Conditions to the Tender Offer Have Been Satisfie...,Investments Ltd. (TASE: CII) announced today that... previously-announced tender offer to purchase,up ...daq: FNDT )(TASE: FNDT),at $12.50 per share, net ...ng taxes and without interest. Clal Industries has...
...enerative Medicine leader to expand space and empl... square feet for new global ... Joined by local officials,and Organogenesis, Inc...nced today that the Massachusetts-based company, w...ide of the state, is initiating an,expansion of it...
Other Biology Technology:Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 3Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 2Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 2Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 4
(Date:12/2/2009)...anpei Suzuki Diabetes Foundation is pleased to ann...Donald F. Steiner, MD, A. N. Pritzker Distinguishe...ine and Biochemistry and Molecular Biology, The Un...urated in 2008 to commemorate the 15th anniversary...g those who have enlightened researchers in the fi...
(Date:12/2/2009)...ore one of your muscles can twitch, before the tho...a tiny floodgate of sortscalled an ion channelmust...to let in the chemical signals that spur the cell ... of Standards and Technology (NIST) has allowed sc...e membrane for the first time, potentially offerin...
(Date:12/2/2009)...c. 2, 2009) HOBOKEN, NJ According to the Nationa... Americans diagnosed with diabetes already have so...pathy, damage to the retina caused by leaky blood ...ith diabetes and is one of the most feared diabeti... patients who,ve had diabetes for 10 years or more...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 1RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 2I Therapeutix Inc Announces Company Name Change 58217 1President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 1President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 2President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 3President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 4President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 5President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 6President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 7President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 8President Clinton Hosts Special Session on Northern Ireland 3B Announces New Commitments Focused on Harnessing Innovation for Development 58215 9
...is available in French . , Researchers at McGill... Institute of the Jewish General Hospital along w... Ottawa Health Research Institute (OHRI) report a ...target and destroy cancer cells, a field known as ...d in the September early edition of the Proceedin...
...mmune system signaling and the production of speci...me primates are able to live with an immunodeficie...ke illness, unlike other primate species, includin...ase. , Following the identification of HIV (Huma...years ago, an extensive search was undertaken to i...
...- Stephen Smiley, Ph.D., a member of the scientifi... could lead to new treatments for several common d...e National Institutes of Health (NIH) for nearly $...atory are working to develop treatments for a numb...od coagulation pathways causes damage to the body....
Other Biology News:Viral 'magic bullet' targets cancer cells with help of new compound 2Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 2Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 3Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS 4Multiple disease-related research gets green light from the NIH 2
Hybridization Buffer from BD Biosciences Pharmingen
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: